NCT00076310 2026-04-15
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
166 trialsNCT00602667 2026-01-13
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT01927744 2025-11-26
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03137771 2025-11-25
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NRG Oncology
Phase 2 Active not recruiting
NCT00977470 2025-10-15
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT00640978 2025-05-01
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00942734 2025-05-01
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00983307 2025-04-30
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Thomas Jefferson University
Phase 2 Completed
NCT00448240 2025-03-18
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
Henry Ford Health System
Phase 2/3 Terminated
NCT00503971 2025-03-07
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Spanish Lung Cancer Group
Phase 1/2 Terminated
NCT00446225 2025-03-05
EURTAC
Spanish Lung Cancer Group
Phase 3 Completed
NCT00720304 2024-08-22
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01064479 2024-07-16
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03076164 2024-04-02
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01174043 2023-10-13
Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
Indiana University
Phase 2 Completed
NCT00597597 2023-05-17
Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer
Rush University Medical Center
Phase 2 Terminated
NCT01180959 2022-11-07
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00553800 2022-07-12
NSCLC
Fox Chase Cancer Center
Phase 2 Completed
NCT00600015 2022-03-10
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00393068 2022-03-02
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00591123 2021-10-01
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Phase 2 Completed
NCT00871923 2021-09-16
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01683422 2021-08-10
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
Loma Linda University
Phase NA Terminated
NCT00570258 2021-03-30
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
University of Arkansas
Phase 2 Terminated
NCT00376948 2021-03-01
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01302808 2021-01-20
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT01573702 2021-01-12
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00888511 2020-11-27
TARLAL
Odense University Hospital
Phase 2 Completed
NCT00033514 2020-10-08
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Jonsson Comprehensive Cancer Center
Phase 1/2 Completed
NCT01532089 2020-10-06
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
Academic and Community Cancer Research United
Phase 2 Completed
NCT00843531 2020-09-29
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Phase 2 Terminated
NCT00950365 2020-09-16
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
Albert Einstein College of Medicine
Phase 2 Completed
NCT00749892 2020-09-10
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00769483 2020-09-03
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01038856 2020-08-24
OSI-TAR-766
University of Oklahoma
Phase 2 Terminated
NCT00547105 2020-08-21
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00278148 2020-07-20
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01857271 2020-07-08
EVENT
Albert Einstein College of Medicine
Phase 2 Terminated
NCT00313560 2020-06-04
ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01192815 2020-05-12
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00402779 2020-04-21
Erlotinib Prevention of Oral Cancer (EPOC)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00539617 2020-03-23
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
University of California, San Francisco
Phase 2 Terminated
NCT00411632 2020-01-29
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01664897 2020-01-07
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00137839 2019-12-17
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02770014 2019-11-22
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00563784 2019-11-20
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00733746 2019-10-21
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed